Adverse effects of proton pump inhibitors in chronic kidney disease

JAMA Internal Medicine

Volumn 176, Issue 6, 2016, Pages 866-

  Fusaro, Maria ^a,c   Giannini, Sandro ^b   Gallieni, Maurizio ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROTON PUMP INHIBITOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7;

ACTIVE TRANSPORT; ACUTE CORONARY SYNDROME; AMINO ACID BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; EX VIVO STUDY; HEMODIALYSIS PATIENT; HUMAN; HYPOMAGNESEMIA; LETTER; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; VASODILATATION; ADVERSE DRUG REACTION; CHRONIC KIDNEY FAILURE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PROTON PUMP INHIBITORS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85047289668     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.1845     Document Type: Letter

References (5)

1. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-246.
2. William JH, Danziger J. Magnesium deficiency and proton-pump inhibitor use: A clinical review [published online November 18, 2015]. J Clin Pharmacol. 2015. doi:10.1002/jcph.672.
3. Fusaro M, Noale M, Tripepi G, et al. Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: A cross-sectional study using propensity score analysis. Drug Saf. 2013;36(8):635-642.
4. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765-771.
5. Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845-853.